Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

24.03
+0.51002.17%
Volume:409.79K
Turnover:9.72M
Market Cap:934.06M
PE:-10.09
High:24.05
Open:23.03
Low:22.81
Close:23.52
52wk High:37.48
52wk Low:5.23
Shares:38.87M
Float Shares:29.65M
Volume Ratio:0.76
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3816
EPS(LYR):-2.1918
ROE:-49.17%
ROA:-26.79%
PB:4.26
PE(LYR):-10.96

Loading ...

Alto Neuroscience President, CFO Nicholas Conrad Smith Disposes of Shares Worth $3,547,660.32

Reuters
·
Oct 02

Alto Neuroscience (ANRO) Defendants Move to Dismiss Third Amended Securities Complaint Over Phase 2b Trial Disclosures

TIPRANKS
·
Sep 23

Alto Neuroscience, Inc. (ANRO) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Alto Neuroscience to Present at H.C. Wainwright Global Healthcare Conference

Reuters
·
Sep 09

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

THOMSON REUTERS
·
Aug 28

Alto Neuroscience Lawsuit Dismissed for Now, With Investors Given Chance to Amend Claims

TIPRANKS
·
Aug 22

Alto Neuroscience Price Target Raised to $55.00/Share from $50.00 by HC Wainwright & Co.

Dow Jones
·
Aug 18

Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright

TIPRANKS
·
Aug 17

Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding?

Simply Wall St.
·
Aug 16

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)

TIPRANKS
·
Aug 14

BofA Adjusts Price Target on Alto Neuroscience to $37 From $33

MT Newswires Live
·
Aug 14

Alto Neuroscience, Inc. (ANRO) Receives a Buy from Jefferies

TIPRANKS
·
Aug 13

Wedbush Adjusts Price Target on Alto Neuroscience to $26 From $24, Keeps Neutral Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Alto Neuroscience Inc : Jefferies Raises Target Price to $40 from $35

THOMSON REUTERS
·
Aug 13

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)

TIPRANKS
·
Aug 13

Alto Neuroscience Posts Corporate Presentation Outlining Precision Psychiatry Drug Pipeline, Led by ALTO-207 in Treatment-Resistant Depression

Reuters
·
Aug 13

Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate

Benzinga Earnings
·
Aug 13

Alto Neuroscience Q2 Net Loss Widens to $27.64 Million; R&D Expenses Rise to $22.11 Million

Reuters
·
Aug 13

Press Release: Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Aug 13